Eupraxia 制药

最新新闻

• Stifel Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  H.C. Wainwright Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
  TipRanks · 2026/9/22
• 评级变动
  Cantor Fitzgerald Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $19
  \u5e02\u573a\u8d44\u8baf · 2026/7/20
• 评级变动
  H.C. Wainwright Remains a Buy on Eupraxia Pharmaceuticals (EPRX)
  TipRanks · 2026/5/4
• A Quick Look at Today's Ratings for Eupraxia Pharmaceuticals(EPRX.US), With a Forecast Between $11 to $16
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Oppenheimer Initiates Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Announces Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2026/6/26
• 评级变动
  Bloom Burton Initiates Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Announces Target Price $14
  \u5e02\u573a\u8d44\u8baf · 2026/2/24
• 评级变动
  Craig-Hallum Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Announces Target Price $14
  \u5e02\u573a\u8d44\u8baf · 2026/5/5
• Wedbush Initiates Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Announces Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  William Blair Initiates Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Announces Target Price $14
  \u5e02\u573a\u8d44\u8baf · 2026/3/23
• 评级变动
  William Blair Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• 评级变动
  Craig-Hallum Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/1/23
• 评级变动
  LifeSci Capital Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $16
  \u5e02\u573a\u8d44\u8baf · 2026/8/27
• Wedbush Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  H.C. Wainwright Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Cuts Target Price to $11
  \u5e02\u573a\u8d44\u8baf · 2026/3/17
• 评级变动
  A Quick Look at Today's Ratings for Eupraxia Pharmaceuticals(EPRX.US), With a Forecast Between $11 to $25
  \u5e02\u573a\u8d44\u8baf · 2026/8/13
• 评级变动
  Oppenheimer Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $17
  \u5e02\u573a\u8d44\u8baf · 2026/6/26
• Bloom Burton Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $14
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  H.C. Wainwright Maintains Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Maintains Target Price $11
  \u5e02\u573a\u8d44\u8baf · 2026/9/22
• 评级变动
  Stifel Initiates Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Announces Target Price $25
  \u5e02\u573a\u8d44\u8baf · 2026/5/21

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。